{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:45:29Z","timestamp":1790217929867,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00280-020-04040-0","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:03:47Z","timestamp":1581707027000},"page":"793-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-7226","authenticated-orcid":false,"given":"Bronwen J.","family":"Mayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate R.","family":"Secombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Wignall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy M.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"10","key":"4040_CR1","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","volume":"13","author":"Q Ryan","year":"2008","unstructured":"Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13(10):1114\u20131119. https:\/\/doi.org\/10.1634\/theoncologist.2008-0816","journal-title":"Oncologist"},{"issue":"36","key":"4040_CR2","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/jco.2013.50.9448","volume":"31","author":"HA Azim Jr","year":"2013","unstructured":"Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG Jr, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E (2013) Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 31(36):4504\u20134511. https:\/\/doi.org\/10.1200\/jco.2013.50.9448","journal-title":"J Clin Oncol"},{"issue":"10","key":"4040_CR3","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/jco.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Dieras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA (2016) Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol 34(10):1034\u20131042. https:\/\/doi.org\/10.1200\/jco.2015.62.1797","journal-title":"J Clin Oncol"},{"key":"4040_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M (2018) Lapatinib. Recent Results Cancer Res 211:19\u201344. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_2","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"4040_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","volume":"112","author":"JP Crown","year":"2008","unstructured":"Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, Parikh R, Oliva C, Preston A, Byrne J, Chan S (2008) Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112(2):317\u2013325. https:\/\/doi.org\/10.1007\/s10549-007-9860-9","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4040_CR6","doi-asserted-by":"publisher","first-page":"e013053","DOI":"10.1136\/bmjopen-2016-013053","volume":"7","author":"ZQ Xu","year":"2017","unstructured":"Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ (2017) Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 7(3):e013053. https:\/\/doi.org\/10.1136\/bmjopen-2016-013053","journal-title":"BMJ Open"},{"issue":"3","key":"4040_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-014-3126-0","volume":"147","author":"G Dranitsaris","year":"2014","unstructured":"Dranitsaris G, Lacouture ME (2014) Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast Cancer Res Treat 147(3):631\u2013638. https:\/\/doi.org\/10.1007\/s10549-014-3126-0","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4040_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s1470-2045(12)70508-9","volume":"14","author":"PE Goss","year":"2013","unstructured":"Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(12)70508-9","journal-title":"Lancet Oncol"},{"key":"4040_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fphar.2018.00516","volume":"9","author":"H Xing","year":"2018","unstructured":"Xing H, Zhang L, Ma J, Liu Z, Song C, Liu Y (2018) Fructus mume extracts alleviate diarrhea in breast cancer patients receiving the combination therapy of lapatinib and capecitabine. Front Pharmacol 9:516. https:\/\/doi.org\/10.3389\/fphar.2018.00516","journal-title":"Front Pharmacol"},{"issue":"3","key":"4040_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00280-014-2519-4","volume":"74","author":"JM Bowen","year":"2014","unstructured":"Bowen JM, Mayo BJ, Plews E, Bateman E, Wignall A, Stringer AM, Boyle FM, Keefe DM (2014) Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol 74(3):617\u2013627. https:\/\/doi.org\/10.1007\/s00280-014-2519-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4040_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05102-x","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L (2019) The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-018-05102-x","journal-title":"Breast Cancer Res Treat"},{"issue":"29_suppl","key":"4040_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/jco.2015.33.29_suppl.205","volume":"33","author":"MO Jamil","year":"2015","unstructured":"Jamil MO, Rizwan M, Carpenter JT (2015) Prophylactic use of antidiarrheal agents to control diarrhea associated with lapatinib therapy in breast cancer patients. J Clin Oncol 33(29_suppl):205\u2013205. https:\/\/doi.org\/10.1200\/jco.2015.33.29_suppl.205","journal-title":"J Clin Oncol"},{"issue":"6","key":"4040_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1634\/theoncologist.2012-0129","volume":"18","author":"FJ Esteva","year":"2013","unstructured":"Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661\u2013666. https:\/\/doi.org\/10.1634\/theoncologist.2012-0129","journal-title":"Oncologist"},{"key":"4040_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fphar.2016.00414","volume":"7","author":"RM McQuade","year":"2016","unstructured":"McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K (2016) Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology Current and Emerging Treatments. Front Pharmacol 7:414. https:\/\/doi.org\/10.3389\/fphar.2016.00414","journal-title":"Front Pharmacol"},{"key":"4040_CR15","doi-asserted-by":"publisher","first-page":"5040176","DOI":"10.1155\/2016\/5040176","volume":"2016","author":"A Upadhyay","year":"2016","unstructured":"Upadhyay A, Bodar V, Malekzadegan M, Singh S, Frumkin W, Mangla A, Doshi K (2016) Loperamide Induced Life Threatening Ventricular Arrhythmia. Case Rep Cardiol 2016:5040176. https:\/\/doi.org\/10.1155\/2016\/5040176","journal-title":"Case Rep Cardiol"},{"issue":"9","key":"4040_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3109\/15563650.2014.969371","volume":"52","author":"JM Marraffa","year":"2014","unstructured":"Marraffa JM, Holland MG, Sullivan RW, Morgan BW, Oakes JA, Wiegand TJ, Hodgman MJ (2014) Cardiac conduction disturbance after loperamide abuse. Clin Toxicol 52(9):952\u2013957. https:\/\/doi.org\/10.3109\/15563650.2014.969371","journal-title":"Clin Toxicol"},{"issue":"13","key":"4040_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.4161\/cbt.21783","volume":"13","author":"JM Bowen","year":"2012","unstructured":"Bowen JM, Mayo BJ, Plews E, Bateman E, Stringer AM, Boyle FM, Finnie JW, Keefe DM (2012) Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther 13(13):1269\u20131275. https:\/\/doi.org\/10.4161\/cbt.21783","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"4040_CR18","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/joe-16-0035","volume":"229","author":"A Amato","year":"2016","unstructured":"Amato A, Baldassano S, Mule F (2016) GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. J Endocrinol 229(2):R57\u201366. https:\/\/doi.org\/10.1530\/joe-16-0035","journal-title":"J Endocrinol"},{"issue":"2","key":"4040_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00280-016-3165-9","volume":"79","author":"BJ Mayo","year":"2017","unstructured":"Mayo BJ, Stringer AM, Bowen JM, Bateman EH, Keefe DM (2017) Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemother Pharmacol 79(2):233\u2013249. https:\/\/doi.org\/10.1007\/s00280-016-3165-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"4040_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1177\/0148607115597644","volume":"40","author":"J Iturrino","year":"2016","unstructured":"Iturrino J, Camilleri M, Acosta A, O'Neill J, Burton D, Edakkanambeth Varayil J, Carlson PJ, Zinsmeister AR, Hurt R (2016) Acute Effects of a glucagon-like peptide 2 analogue, teduglutide, on gastrointestinal motor function and permeability in adult patients with short bowel syndrome on home parenteral nutrition. JPEN 40(8):1089\u20131095. https:\/\/doi.org\/10.1177\/0148607115597644","journal-title":"JPEN"},{"issue":"1","key":"4040_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-012-1882-2","volume":"70","author":"H Kissow","year":"2012","unstructured":"Kissow H, Viby NE, Hartmann B, Holst JJ, Timm M, Thim L, Poulsen SS (2012) Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemother Pharmacol 70(1):39\u201348. https:\/\/doi.org\/10.1007\/s00280-012-1882-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"4040_CR22","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1158\/1078-0432.ccr-07-0574","volume":"13","author":"KJ Hare","year":"2007","unstructured":"Hare KJ, Hartmann B, Kissow H, Holst JJ, Poulsen SS (2007) The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 13(17):5170\u20135175. https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-0574","journal-title":"Clin Cancer Res"},{"issue":"Supplement 8","key":"4040_CR23","first-page":"134","volume":"10","author":"B Mayo","year":"2014","unstructured":"Mayo B, Bateman E, Stringer A, Plews E, Wignall A, Wozniak B, White I, Pietra C, Cantoreggi S, Keefe D (2014) The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Asia-Pacific J Clin Oncol 10(Supplement 8):134","journal-title":"Asia-Pacific J Clin Oncol"},{"issue":"23","key":"4040_CR24","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.1158\/1078-0432.ccr-15-0724","volume":"21","author":"SK Pal","year":"2015","unstructured":"Pal SK, Li SM, Wu X, Qin H, Kortylewski M, Hsu J, Carmichael C, Frankel P (2015) Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors. Clin Cancer Res 21(23):5286\u20135293. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-0724","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4040_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/0016-5085(84)90202-6","volume":"87","author":"JE Krawisz","year":"1984","unstructured":"Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87(6):1344\u20131350","journal-title":"Gastroenterology"},{"issue":"9","key":"4040_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1046\/j.1440-1746.2003.03136.x","volume":"18","author":"RJ Gibson","year":"2003","unstructured":"Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18(9):1095\u20131100","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4040_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2613.2009.00671.x","volume":"90","author":"AM Stringer","year":"2009","unstructured":"Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N, Keefe DM (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90(5):489\u2013499. https:\/\/doi.org\/10.1111\/j.1365-2613.2009.00671.x","journal-title":"Int J Exp Pathol"},{"issue":"5","key":"4040_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nmeth.f.303","volume":"7","author":"JG Caporaso","year":"2010","unstructured":"Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7(5):335\u2013336. https:\/\/doi.org\/10.1038\/nmeth.f.303","journal-title":"Nat Methods"},{"issue":"16","key":"4040_CR29","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/bioinformatics\/bts342","volume":"28","author":"J Chen","year":"2012","unstructured":"Chen J, Bittinger K, Charlson ES, Hoffmann C, Lewis J, Wu GD, Collman RG, Bushman FD, Li H (2012) Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics 28(16):2106\u20132113. https:\/\/doi.org\/10.1093\/bioinformatics\/bts342","journal-title":"Bioinformatics"},{"key":"4040_CR30","doi-asserted-by":"crossref","DOI":"10.4324\/9780203211250","volume-title":"Diseases of the wistar rat","author":"MJ Tucker","year":"1997","unstructured":"Tucker MJ (1997) Diseases of the wistar rat. Taylor & Francis, London, Bristol"},{"issue":"6","key":"4040_CR31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.mct-15-0990","volume":"15","author":"HR Wardill","year":"2016","unstructured":"Wardill HR, Gibson RJ, Van Sebille YZ, Secombe KR, Coller JK, White IA, Manavis J, Hutchinson MR, Staikopoulos V, Logan RM, Bowen JM (2016) Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. Mol Cancer Ther 15(6):1376\u20131386. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0990","journal-title":"Mol Cancer Ther"},{"key":"4040_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1500","author":"GM Slim","year":"2019","unstructured":"Slim GM, Lansing M, Wizzard P, Nation PN, Wheeler SE, Brubaker PL, Jeppesen PB, Wales PW, Turner JM (2019) Novel Long-Acting GLP2 Analogue, Apraglutide, Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. https:\/\/doi.org\/10.1002\/jpen.1500","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"4040_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/sj.ijo.0802247","volume":"27","author":"LB Sorensen","year":"2003","unstructured":"Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A (2003) No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metabol Disord 27(4):450\u2013456. https:\/\/doi.org\/10.1038\/sj.ijo.0802247","journal-title":"Int J Obes Relat Metabol Disord"},{"issue":"12","key":"4040_CR34","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/ijc.30699","volume":"140","author":"YZA Van Sebille","year":"2017","unstructured":"Van Sebille YZA, Gibson RJ, Wardill HR, Secombe KR, Ball IA, Keefe DMK, Finnie JW, Bowen JM (2017) Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. Int J Cancer J Int Cancer 140(12):2820\u20132829. https:\/\/doi.org\/10.1002\/ijc.30699","journal-title":"Int J Cancer J Int Cancer"},{"issue":"5","key":"4040_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/annonc\/mdl332","volume":"18","author":"N Blijlevens","year":"2007","unstructured":"Blijlevens N, Sonis S (2007) Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 18(5):817\u2013826. https:\/\/doi.org\/10.1093\/annonc\/mdl332","journal-title":"Ann Oncol"},{"issue":"3","key":"4040_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ijc.21082","volume":"116","author":"RJ Gibson","year":"2005","unstructured":"Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer J Int Cancer 116(3):464\u2013470. https:\/\/doi.org\/10.1002\/ijc.21082","journal-title":"Int J Cancer J Int Cancer"},{"issue":"11","key":"4040_CR37","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/jcmm.12169","volume":"17","author":"S Vadhan-Raj","year":"2013","unstructured":"Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR (2013) Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med 17(11):1371\u20131384. https:\/\/doi.org\/10.1111\/jcmm.12169","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4040_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00280-017-3364-z","volume":"80","author":"RA Forsgard","year":"2017","unstructured":"Forsgard RA, Marrachelli VG, Korpela K, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Osterlund P (2017) Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemother Pharmacol 80(2):317\u2013332. https:\/\/doi.org\/10.1007\/s00280-017-3364-z","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04040-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-020-04040-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04040-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T21:03:16Z","timestamp":1613250196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-020-04040-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4040"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04040-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bronwen Mayo, Kate Secombe, Anthony Wignall, Emma Bateman and Daniel Thorpe declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted (SA Pathology and The University of Adelaide). This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}